186 related articles for article (PubMed ID: 37582911)
21. mRNA vaccination drives differential mucosal neutralizing antibody profiles in naïve and SARS-CoV-2 previously-infected individuals.
Longet S; Hargreaves A; Healy S; Brown R; Hornsby HR; Meardon N; Tipton T; Barnes E; Dunachie S; Duncan CJA; Klenerman P; Richter A; Turtle L; de Silva TI; Carroll MW
Front Immunol; 2022; 13():953949. PubMed ID: 36159846
[TBL] [Abstract][Full Text] [Related]
22. 25-Hydroxyvitamin D concentrations do not affect the humoral or cellular immune response following SARS-CoV-2 mRNA vaccinations.
Lavell AHA; Schramade AE; Sikkens JJ; van der Straten K; van Dort KA; Slim MA; Appelman B; van Vught LA; Vlaar APJ; Kootstra NA; van Gils MJ; Smulders YM; de Jongh RT; Bomers MK;
Vaccine; 2024 Mar; 42(7):1478-1486. PubMed ID: 37775466
[TBL] [Abstract][Full Text] [Related]
23. Humoral and cellular immunity to SARS-COV-2 after vaccination with mRNA vaccines in PLWH with discordant immune response. Influence of the vaccine administered.
López-Cortés LF; Saborido-Alconchel A; Trujillo-Rodríguez M; Serna-Gallego A; Llaves-Flores S; Muñoz-Muela E; Pérez-Santos MJ; Lozano C; Mejias-Trueba M; Roca C; Espinosa N; Gutiérrez-Valencia A
Front Immunol; 2023; 14():1129753. PubMed ID: 37006309
[TBL] [Abstract][Full Text] [Related]
24. Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273.
Verstegen NJM; Hagen RR; van den Dijssel J; Kuijper LH; Kreher C; Ashhurst T; Kummer LYL; Steenhuis M; Duurland M; de Jongh R; de Jong N; van der Schoot CE; Bos AV; Mul E; Kedzierska K; van Dam KPJ; Stalman EW; Boekel L; Wolbink G; Tas SW; Killestein J; van Kempen ZLE; Wieske L; Kuijpers TW; Eftimov F; Rispens T; van Ham SM; Ten Brinke A; van de Sandt CE;
Elife; 2022 Jul; 11():. PubMed ID: 35838348
[TBL] [Abstract][Full Text] [Related]
25. Persistence of Immune Response Elicited by Three Doses of mRNA Vaccine against SARS-CoV-2 in a Cohort of Patients with Solid Tumors: A One-Year Follow-Up.
Lasagna A; Cassaniti I; Arena F; Bergami F; Percivalle E; Comolli G; Sarasini A; Ferrari A; Cicognini D; Schiavo R; Lo Cascio G; Pedrazzoli P; Baldanti F
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047704
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients.
Becker M; Cossmann A; Lürken K; Junker D; Gruber J; Juengling J; Ramos GM; Beigel A; Wrenger E; Lonnemann G; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Strengert M; Dulovic A; Behrens GMN
Front Immunol; 2022; 13():1004045. PubMed ID: 36275672
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of Humoral and Cellular Responses in SARS-CoV-2 mRNA Vaccinated Immunocompromised Patients.
Oyaert M; De Scheerder MA; Van Herrewege S; Laureys G; Van Assche S; Cambron M; Naesens L; Hoste L; Claes K; Haerynck F; Kerre T; Van Laecke S; Van Biesen W; Jacques P; Verhasselt B; Padalko E
Front Immunol; 2022; 13():858399. PubMed ID: 35401575
[TBL] [Abstract][Full Text] [Related]
28. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis.
Limoges MA; Lortie A; Demontier É; Quenum AJI; Lessard F; Drouin Z; Carrier N; Nguimbus LM; Beaulieu MC; Boire G; Piché A; Allard-Chamard H; Ramanathan S; Roux S
J Leukoc Biol; 2023 Sep; 114(4):358-367. PubMed ID: 37478373
[TBL] [Abstract][Full Text] [Related]
30. BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.
Moyon Q; Sterlin D; Miyara M; Anna F; Mathian A; Lhote R; Ghillani-Dalbin P; Breillat P; Mudumba S; de Alba S; Cohen-Aubart F; Haroche J; Pha M; Boutin THD; Chaieb H; Flores PM; Charneau P; Gorochov G; Amoura Z
Ann Rheum Dis; 2022 Apr; 81(4):575-583. PubMed ID: 34607791
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases.
Hadjadj J; Planas D; Ouedrani A; Buffier S; Delage L; Nguyen Y; Bruel T; Stolzenberg MC; Staropoli I; Ermak N; Macraigne L; Morbieu C; Henriquez S; Veyer D; Péré H; Casadevall M; Mouthon L; Rieux-Laucat F; Chatenoud L; Schwartz O; Terrier B
Ann Rheum Dis; 2022 May; 81(5):720-728. PubMed ID: 35022159
[TBL] [Abstract][Full Text] [Related]
32. Rheumatoid arthritis patients treated with Janus kinase inhibitors show reduced humoral immune responses following BNT162b2 vaccination.
Iancovici L; Khateeb D; Harel O; Peri R; Slobodin G; Hazan Y; Melamed D; Kessel A; Bar-On Y
Rheumatology (Oxford); 2022 Aug; 61(8):3439-3447. PubMed ID: 34849628
[TBL] [Abstract][Full Text] [Related]
33. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
[TBL] [Abstract][Full Text] [Related]
34. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: A prospective cohort study.
Leong DP; Zhang A; Breznik JA; Clare R; Huynh A; Mushtaha M; Rangarajan S; Stacey H; Kim PY; Loeb M; Denburg JA; Mertz D; Chagla Z; Nazy I; Miller MS; Bowdish DME; Duong M
PLoS One; 2023; 18(2):e0281673. PubMed ID: 36791069
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine.
Sheng WH; Ieong SM; Lin PH; Hsieh MJ; Yang HC; Pan CF; Chao TL; Chang SY; Chang SC
J Formos Med Assoc; 2023 Feb; 122(2):121-131. PubMed ID: 36127206
[TBL] [Abstract][Full Text] [Related]
36. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
[TBL] [Abstract][Full Text] [Related]
37. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.
Dayam RM; Law JC; Goetgebuer RL; Chao GY; Abe KT; Sutton M; Finkelstein N; Stempak JM; Pereira D; Croitoru D; Acheampong L; Rizwan S; Rymaszewski K; Milgrom R; Ganatra D; Batista NV; Girard M; Lau I; Law R; Cheung MW; Rathod B; Kitaygorodsky J; Samson R; Hu Q; Hardy WR; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Gingras AC; Watts TH
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471956
[TBL] [Abstract][Full Text] [Related]
38. Profile of humoral and cellular immune responses to single doses of BNT162b2 or ChAdOx1 nCoV-19 vaccines in residents and staff within residential care homes (VIVALDI): an observational study.
Tut G; Lancaster T; Krutikov M; Sylla P; Bone D; Kaur N; Spalkova E; Bentley C; Amin U; Jadir AT; Hulme S; Butler MS; Ayodele M; Bruton R; Shrotri M; Azmi B; Fuller C; Irwin-Singer A; Hayward A; Copas A; Shallcross L; Moss P
Lancet Healthy Longev; 2021 Sep; 2(9):e544-e553. PubMed ID: 34430954
[TBL] [Abstract][Full Text] [Related]
39. Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection.
Hyun H; Jang AY; Park H; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Seok JH; Kim J; Park MS; Song JY
Front Immunol; 2023; 14():1131229. PubMed ID: 36960070
[TBL] [Abstract][Full Text] [Related]
40. Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer.
Debie Y; Van Audenaerde JRM; Vandamme T; Croes L; Teuwen LA; Verbruggen L; Vanhoutte G; Marcq E; Verheggen L; Le Blon D; Peeters B; Goossens ME; Pannus P; Ariën KK; Anguille S; Janssens A; Prenen H; Smits ELJ; Vulsteke C; Lion E; Peeters M; van Dam PA
Clin Cancer Res; 2023 Feb; 29(3):635-646. PubMed ID: 36341493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
